A Tufts Center for the Study of Drug Development analysis said an agentic AI clinical monitoring tool can generate material net financial gains in oncology programs, with modeled expected ROI up to 82x in phase 3. The report, based on benchmarked oncology trial data and contract value inputs from Medable, quantified improvements across eNPV gains, on-site visit reduction, and accelerated administrative timelines. Tufts estimated eNPV gains of about $7.5 million in phase 2, $11.3 million across combined phase 2/3 development, and as much as $21 million in phase 3. The analysis also projected reductions in direct operating costs for on-site monitoring and estimated that agentic AI could accelerate development timelines by roughly 10 weeks. While financial modeling does not substitute for clinical efficacy, the work adds to the operational case for AI tools focused on enrollment, monitoring workflow, and database lock acceleration—areas that can constrain trial timelines and budgets.